An explanation for the different inhibitory characteristics of human serum butyrylcholinesterase phenotypes deriving from inhibition of atypical heterozygotes

Chemico-Biological Interactions

Volumn 119-120, Issue , 1999, Pages 159-164

  Simeon Rudolf, Vera ^a   Kovarik, Zrinka ^a   Škrinjarić Špoljar, Mira ^a   Evans, Robert T ^b  

^a INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

^b NONE

Author keywords

Atypical variant; Butyrylcholinesterase; Human serum cholinesterase

Indexed keywords

CARBAMIC ACID DERIVATIVE; CHOLINESTERASE; CINCHOCAINE; ENZYME VARIANT; FLUORIDE SODIUM; RO 02 0683; UNCLASSIFIED DRUG;

CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; HETEROZYGOTE; HUMAN; MUTATION; PHENOTYPE;

APNEA; BUTYRYLCHOLINESTERASE; CARBAMATES; CHOLINESTERASE INHIBITORS; DIBUCAINE; HETEROZYGOTE DETECTION; HUMANS; KINETICS; NEUROMUSCULAR DEPOLARIZING AGENTS; PHENOTYPE; QUATERNARY AMMONIUM COMPOUNDS; SODIUM FLUORIDE; SUCCINYLCHOLINE; THIOCHOLINE;

EID: 0033002758     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(99)00024-1     Document Type: Conference Paper

References (11)

1. Kalow W., Genest K. A method for the detection of atypical forms of human serum cholinesterase, Determination of dibucaine numbers. Can. J. Biochem. Physiol. 35:1957;339-346.
2. Whittaker M. Cholinesterase. Monographs in Human Genetics. 11:1986;1-132 Karger, Basel.
3. Evans R.T. Cholinesterase phenotyping: Clinical aspects and laboratory applications. Crit. Rev. Clin. Laboratory Sci. 23:1986;35-64.
4. Lockridge O. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmac. Ther. 47:1990;35-60.
5. Bartels C.F., Jensen F.S., Lockridge O., van der Spek A.F.L., Rubinstein H.M., Lubrano T., La Du B.N. The DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am. J. Hum. Genet. 50:1992;1086-1103.
6. Bartels C.F., James K., La Du B.N. DNA mutations associated with the human butyrylcholinesterase J-variant. Am. J. Hum. Genet. 50:1992;1104-1114.
7. Kalow W., Davies R.O. The activity of various esterase inhibitors towards atypical human serum cholinesterase. Biochem. Pharmacol. 1:1958;183-192.
8. Ellman G.L., Courtney K.D., Andres, Jr V., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95.
9. Prester Lj., Simeon V. Kinetics of the inhibition of human serum cholinesterase phenotypes with the dimethylcarbamate of (2-hydroxy-5-phenylbenzyl)-trimethylammonium bromide (Ro 02-0683). Biochem. Pharmacol. 42:1991;2313-2316.
10. Aldridge W.N., Reiner E. Enzyme Inhibitors as Substrates: Interaction of Esterases with Esters of Organophosphorus and Carbamic Acids, XV+328. 1972;North Holland, Amsterdam.
11. 1, a quantitative variant at cholinesterase locus 1: immunological evidence. J. Med. Genet. 13:1976;43-45.